Loading clinical trials...
Loading clinical trials...
A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors
Conditions
Interventions
DM002
Locations
5
United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
The University of Texas, MD Anderson Cancer Center
Houston, Texas, United States
Scientia Clinical Research
Randwick, New South Wales, Australia
Cancer Care Wollongong
Wollongong, New South Wales, Australia
Southern Oncology Clinical Research Unit
Adelaide, South Australia, Australia
Start Date
February 17, 2025
Primary Completion Date
October 8, 2027
Completion Date
April 18, 2028
Last Updated
January 15, 2026
NCT04895709
NCT06190899
NCT07213804
NCT07225946
NCT07046923
NCT06051695
Lead Sponsor
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions